Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study

B. Cartmel, T. E. Moon, N. Levine, S. Rodney, David S Alberts

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Maintaining good compliance is a major challenge in long-term cancer chemoprevention trials. Minimizing the number of inactive participants during a trial is an important factor in maximizing compliance. Identifying reasons for and predictors of inactivation is the first step in being able to reduce participant inactivation. In this skin cancer chemoprevention trial, the 2,297 participants were randomized to receive 25,000 IU of retinol daily or a placebo. Median follow-up time was 3.8 years. The reason for inactivation was determined for each participant who stopped taking the study capsules. Six hundred and seventy-seven (29.7%) participants became inactive during the 5-year study. There was no significant difference between the number of participants inactivating by treatment group or sex. The most common reasons for inactivation were illness of subject, spouse, or a close relative (18.6%) and experience of a clinical symptom consistent with vitamin A ingestion (17.1%). Participants in the vitamin A group (10.1%) more frequently cited symptoms coded as 'not consistent with vitamin A' as the reason for inactivation compared with those in the placebo group [5.4% (P < 0.05)]. The inactivation rate was highest in the first month of the trial and declined thereafter. A low education level (hazard ratio, 1.59) and unmarried status (hazard ratio, 1.29) were the only significant predictors of inactivation. These findings may be useful in developing targeted strategies to decrease inactivation and thereby increase compliance in future chemoprevention trials. However, these findings need to be confirmed because published research in this area is very limited.

Original languageEnglish (US)
Pages (from-to)999-1002
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume9
Issue number9
StatePublished - 2000
Externally publishedYes

Fingerprint

Chemoprevention
Skin Neoplasms
Vitamin A
Compliance
Placebos
Spouses
Capsules
Eating
Education
Research
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study. / Cartmel, B.; Moon, T. E.; Levine, N.; Rodney, S.; Alberts, David S.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 9, No. 9, 2000, p. 999-1002.

Research output: Contribution to journalArticle

@article{94ee9ea4c21447ce9fdcf978adae0430,
title = "Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study",
abstract = "Maintaining good compliance is a major challenge in long-term cancer chemoprevention trials. Minimizing the number of inactive participants during a trial is an important factor in maximizing compliance. Identifying reasons for and predictors of inactivation is the first step in being able to reduce participant inactivation. In this skin cancer chemoprevention trial, the 2,297 participants were randomized to receive 25,000 IU of retinol daily or a placebo. Median follow-up time was 3.8 years. The reason for inactivation was determined for each participant who stopped taking the study capsules. Six hundred and seventy-seven (29.7{\%}) participants became inactive during the 5-year study. There was no significant difference between the number of participants inactivating by treatment group or sex. The most common reasons for inactivation were illness of subject, spouse, or a close relative (18.6{\%}) and experience of a clinical symptom consistent with vitamin A ingestion (17.1{\%}). Participants in the vitamin A group (10.1{\%}) more frequently cited symptoms coded as 'not consistent with vitamin A' as the reason for inactivation compared with those in the placebo group [5.4{\%} (P < 0.05)]. The inactivation rate was highest in the first month of the trial and declined thereafter. A low education level (hazard ratio, 1.59) and unmarried status (hazard ratio, 1.29) were the only significant predictors of inactivation. These findings may be useful in developing targeted strategies to decrease inactivation and thereby increase compliance in future chemoprevention trials. However, these findings need to be confirmed because published research in this area is very limited.",
author = "B. Cartmel and Moon, {T. E.} and N. Levine and S. Rodney and Alberts, {David S}",
year = "2000",
language = "English (US)",
volume = "9",
pages = "999--1002",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study

AU - Cartmel, B.

AU - Moon, T. E.

AU - Levine, N.

AU - Rodney, S.

AU - Alberts, David S

PY - 2000

Y1 - 2000

N2 - Maintaining good compliance is a major challenge in long-term cancer chemoprevention trials. Minimizing the number of inactive participants during a trial is an important factor in maximizing compliance. Identifying reasons for and predictors of inactivation is the first step in being able to reduce participant inactivation. In this skin cancer chemoprevention trial, the 2,297 participants were randomized to receive 25,000 IU of retinol daily or a placebo. Median follow-up time was 3.8 years. The reason for inactivation was determined for each participant who stopped taking the study capsules. Six hundred and seventy-seven (29.7%) participants became inactive during the 5-year study. There was no significant difference between the number of participants inactivating by treatment group or sex. The most common reasons for inactivation were illness of subject, spouse, or a close relative (18.6%) and experience of a clinical symptom consistent with vitamin A ingestion (17.1%). Participants in the vitamin A group (10.1%) more frequently cited symptoms coded as 'not consistent with vitamin A' as the reason for inactivation compared with those in the placebo group [5.4% (P < 0.05)]. The inactivation rate was highest in the first month of the trial and declined thereafter. A low education level (hazard ratio, 1.59) and unmarried status (hazard ratio, 1.29) were the only significant predictors of inactivation. These findings may be useful in developing targeted strategies to decrease inactivation and thereby increase compliance in future chemoprevention trials. However, these findings need to be confirmed because published research in this area is very limited.

AB - Maintaining good compliance is a major challenge in long-term cancer chemoprevention trials. Minimizing the number of inactive participants during a trial is an important factor in maximizing compliance. Identifying reasons for and predictors of inactivation is the first step in being able to reduce participant inactivation. In this skin cancer chemoprevention trial, the 2,297 participants were randomized to receive 25,000 IU of retinol daily or a placebo. Median follow-up time was 3.8 years. The reason for inactivation was determined for each participant who stopped taking the study capsules. Six hundred and seventy-seven (29.7%) participants became inactive during the 5-year study. There was no significant difference between the number of participants inactivating by treatment group or sex. The most common reasons for inactivation were illness of subject, spouse, or a close relative (18.6%) and experience of a clinical symptom consistent with vitamin A ingestion (17.1%). Participants in the vitamin A group (10.1%) more frequently cited symptoms coded as 'not consistent with vitamin A' as the reason for inactivation compared with those in the placebo group [5.4% (P < 0.05)]. The inactivation rate was highest in the first month of the trial and declined thereafter. A low education level (hazard ratio, 1.59) and unmarried status (hazard ratio, 1.29) were the only significant predictors of inactivation. These findings may be useful in developing targeted strategies to decrease inactivation and thereby increase compliance in future chemoprevention trials. However, these findings need to be confirmed because published research in this area is very limited.

UR - http://www.scopus.com/inward/record.url?scp=0033796639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033796639&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 999

EP - 1002

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 9

ER -